Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective phase IV adalimumab study in rheumatoid arthritis
NL-OMON20706Phase 4Active, not recruiting
- Sponsor
- AMC Health
- Start
- Apr 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of adalimumab in rheumatoid arthritis (RA), sponsored by AMC Health. Primary endpoints: Clinical efficacy at week 16 and Markers distinguishing responders from non-responders. Started Apr 2004; status: active, not recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON20706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20706.